NASDAQ$FABC

StableX Technologies Inc · Q1 2025 earnings

Q1 2025 earnings · · After market close · Investor relations

Briefing

First Advantage Bancorp reported Q1 2025 a net loss of $1.7M, diluted EPS of $-0.20.

For Q1 2025, First Advantage Bancorp reported net loss was $1.7M, diluted EPS was $-0.20. The quarterly filing discusses operating priorities, liquidity, and sector-specific risks in MD&A.

  • Net loss $1.7M.
  • Diluted EPS $-0.20.
  • MD&A highlights cash runway, pipeline progress, and macro risks.

Headline financials

Total Revenue

$0.00

Previous: $58.4K-100.0%
EPS (adj)

-$0.20

Previous: -$1.46+86.3%
Common Stock Outstanding

8.5M

No prior period
Accrued Preferred Stock Redemption Payable (H-7)

$4.48M

No prior period
Warranty Liability

$1.28M

No prior period
Lease Obligation - Operating Lease, Net of Current Portion

$224K

No prior period
Sales and Marketing Expense

$0.00

No prior period
Change in Fair Value - Warrant Liability

$1.08M

No prior period
Marketable securities

$2.48M

No prior period
Total current assets

$15.7M

No prior period
Accounts payable

$1.66M

No prior period
Current lease obligation

$227K

No prior period
Total current liabilities

$7.15M

No prior period
Derivative liability

$1.13M

No prior period
Total liabilities

$9.78M

No prior period
Series H-7 preferred stock

$3.36M

No prior period
Total stockholders' equity

$3.01M

No prior period
R&D expense

$308K

No prior period
G&A expense

$1.67M

No prior period
Total operating expenses

$1.97M

No prior period
Interest income

$26.2K

No prior period
Change in derivative liability

$1.53M

No prior period
Unrealized loss on securities

-$71.7K

No prior period
Realized gain on securities

$211K

No prior period
Other income net

$41.4K

No prior period
Total other income net

$2.82M

No prior period
Net cash used in operations

-$1.48M

No prior period
Net cash from investing

$1.75M

No prior period
Net cash used in financing

-$3.55M

No prior period
Restricted cash

$109K

No prior period
Accrued expenses

$780K

No prior period
Net Income

-$1.68M

Previous: -$7.19M+76.7%
Operating Income

-$1.97M

Previous: -$5.22M+62.2%
Gross Profit

$0.00

Previous: -$1.12M+100.0%

Revenue & EPS history

AYRO · Revenue · Quarterly

$0

Q1 2025-100%vs Q1 2024
Beat estimate in 2 of 11 quarters(18%)
ActualEstimate

Forward guidance

Outlook emphasizes clinical milestones, cash runway, and operating expense discipline.

Tailwinds

  • Pipeline progress and partnership optionality.
  • Cost controls and balance-sheet flexibility.

Headwinds

  • Operating losses until commercialization.
  • Trial timing and regulatory uncertainty.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2025

Historical avgQ1 2025

-0.8%

Avg return

Earnings day

-4.3%

Avg return

5 days after

-6.1%

Avg return

30 days after

38%

21 / 55 earnings

Positive

+31.1%

Q1 2015

Best reaction

-16.7%

Q4 2009

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q3 2025+12.7%-22.2%+10.6%
Q2 2025-2.9%-10.2%-20.9%
Q1 2025+1.6%-4.9%+15.2%
Q4 2024+2.8%+2.0%-20.0%
Q3 2024-0.5%-5.1%+3.8%
Q2 2024+3.9%+15.3%+13.9%
Q1 2024-1.8%-1.8%-31.6%
Q1 2026+1.6%-6.6%-28.7%
Q4 2023-0.6%-7.2%-25.1%
Q3 2023+4.6%+18.3%+16.6%
Q2 2023-4.8%+4.8%-24.2%
Q1 2023-2.0%+7.8%+11.8%
Q4 2022+3.6%-5.4%+1.8%
Q3 2022-6.7%-8.3%-1.7%
Q2 2022+2.8%-1.8%-22.9%
Q1 2022+2.9%-6.7%+0.0%
Q4 2021-4.7%-11.4%-30.9%
Q3 2021-6.2%-17.6%-34.3%
Q2 2021+0.2%-5.5%-8.5%
Q1 2021+6.8%+15.9%+33.3%
Q4 2020+5.3%-0.8%-11.5%
Q3 2020-3.6%-5.9%+120.5%
Q2 2020-8.2%-15.6%-32.0%
Q1 2020+21.0%+23.5%-35.8%
Q4 2019-4.3%-19.1%+19.1%
Q3 2019-3.1%-1.6%-7.8%
Q2 2019+2.6%-3.8%+3.8%
Q1 2019-10.3%-23.8%-37.0%
Q4 2018-10.3%-23.8%-37.0%
Q3 2018+0.0%-7.5%-15.0%
Q2 2018-10.2%-10.2%-31.8%
Q1 2018-7.9%-3.0%-18.9%
Q3 2017-1.1%-1.7%-10.9%
Q2 2017-3.0%-4.5%-9.0%
Q1 2017-0.7%-6.7%+8.9%
Q4 2016-2.7%-3.4%-18.1%
Q3 2016-0.8%-1.6%+28.7%
Q4 2015+7.9%
Q2 2015-11.5%
Q1 2016-16.2%
Q1 2015+31.1%
Q4 2014+16.7%
Q3 2014-9.1%
Q2 2014+2.3%
Q4 2013+7.1%
Q3 2013-2.2%
Q2 2013-4.6%
Q4 2012+7.0%
Q3 2012-2.3%
Q4 2011-14.7%
Q2 2012-3.5%
Q2 2010-3.5%
Q1 2011+1.0%
Q4 2010-6.6%
Q4 2009-16.7%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro